Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Pharmaceutics (2019) 11(12):681
TB-500, by contrast, works systemically
Dont tough it out if you cant keep fluids down
In December 2023, Gilead Sciences announced an agreement with Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate, a high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby releasing natural IL-18 in the tumor microenvironment and inhibiting cancer growth
US$ 23.87
US$ 27.47
US$ 27.33
US$ 29.25
US$ 21.40
US$ 21.73
US$ 22.82
US$ 23.85
US$ 28.34
US$ 20.20
US$ 22.51
US$ 21.11
